TWI747178B - 單鏈trail-受體激動劑蛋白質 - Google Patents
單鏈trail-受體激動劑蛋白質 Download PDFInfo
- Publication number
- TWI747178B TWI747178B TW109106778A TW109106778A TWI747178B TW I747178 B TWI747178 B TW I747178B TW 109106778 A TW109106778 A TW 109106778A TW 109106778 A TW109106778 A TW 109106778A TW I747178 B TWI747178 B TW I747178B
- Authority
- TW
- Taiwan
- Prior art keywords
- trail
- receptor agonist
- seq
- domain
- protein
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983152P | 2014-04-23 | 2014-04-23 | |
| US61/983,152 | 2014-04-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202024123A TW202024123A (zh) | 2020-07-01 |
| TWI747178B true TWI747178B (zh) | 2021-11-21 |
Family
ID=53055121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109106778A TWI747178B (zh) | 2014-04-23 | 2015-04-23 | 單鏈trail-受體激動劑蛋白質 |
| TW104113087A TWI683825B (zh) | 2014-04-23 | 2015-04-23 | 單鏈trail-受體激動劑蛋白質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104113087A TWI683825B (zh) | 2014-04-23 | 2015-04-23 | 單鏈trail-受體激動劑蛋白質 |
Country Status (38)
| Country | Link |
|---|---|
| US (5) | US9908927B2 (2) |
| EP (2) | EP3366699A1 (2) |
| JP (2) | JP6523331B2 (2) |
| KR (2) | KR20190135546A (2) |
| CN (2) | CN106459221B (2) |
| AR (1) | AR100168A1 (2) |
| AU (3) | AU2015249649B2 (2) |
| BR (1) | BR112016024515B1 (2) |
| CA (2) | CA2946402C (2) |
| CL (1) | CL2016002683A1 (2) |
| CR (1) | CR20160516A (2) |
| CY (1) | CY1120281T1 (2) |
| DK (1) | DK3134430T3 (2) |
| DO (1) | DOP2016000284A (2) |
| EC (1) | ECSP16089579A (2) |
| ES (1) | ES2672368T3 (2) |
| HR (1) | HRP20180950T1 (2) |
| HU (1) | HUE038914T2 (2) |
| IL (2) | IL248244B (2) |
| LT (1) | LT3134430T (2) |
| MA (2) | MA39770A (2) |
| MX (2) | MX2016013858A (2) |
| MY (1) | MY181986A (2) |
| NO (1) | NO2776305T3 (2) |
| PE (1) | PE20170299A1 (2) |
| PH (2) | PH12020500377A1 (2) |
| PL (1) | PL3134430T3 (2) |
| PT (1) | PT3134430T (2) |
| RS (1) | RS57153B1 (2) |
| RU (1) | RU2699285C2 (2) |
| SG (3) | SG10202111785VA (2) |
| SI (1) | SI3134430T1 (2) |
| SM (1) | SMT201800286T1 (2) |
| TR (1) | TR201806912T4 (2) |
| TW (2) | TWI747178B (2) |
| UA (1) | UA118286C2 (2) |
| UY (1) | UY36095A (2) |
| WO (1) | WO2015164588A1 (2) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2754432T3 (es) * | 2015-05-04 | 2020-04-17 | Apogenix Ag | Proteínas agonistas de receptor CD40 de cadena sencilla |
| CA3002741A1 (en) * | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain gitr-receptor agonist proteins |
| CA3002587A1 (en) * | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain light receptor agonist proteins |
| EP3364995B1 (en) | 2015-10-23 | 2021-08-04 | Apogenix AG | Single-chain cd27-receptor agonist proteins |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| CA3054286A1 (en) | 2016-03-01 | 2017-09-08 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability |
| AU2017234679A1 (en) * | 2016-03-16 | 2018-08-30 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
| US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| JP2019517570A (ja) * | 2016-06-13 | 2019-06-24 | メリマック ファーマシューティカルズ インコーポレーティッド | Trailベースの治療剤または細胞死受容体アゴニストを用いて患者を選択および治療する方法 |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| JP7744621B2 (ja) * | 2017-08-11 | 2025-09-26 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 切断されたモルモットl-アスパラギナーゼバリアントおよび使用の方法 |
| TW202002952A (zh) | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | 用於治療胰臟癌之abbv-621與抗癌劑之組合 |
| WO2019178438A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of cancer |
| EP4149964A2 (en) | 2020-05-15 | 2023-03-22 | Apogenix AG | Multi-specific immune modulators |
| AU2022281108A1 (en) | 2021-05-28 | 2023-12-14 | Julius-Maximilians-Universität Würzburg | Recombinant proteinaceous binding molecules |
| WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010010051A1 (en) * | 2008-07-21 | 2010-01-28 | Apogenix Gmbh | Tnfsf single chain molecules |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001025277A1 (en) | 1999-10-07 | 2001-04-12 | Maxygen Aps | Single-chain antagonist polypeptides |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
| IL155812A0 (en) * | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| WO2003091447A2 (en) * | 2002-04-26 | 2003-11-06 | California Institute Of Technology | D1-1 nucleic acids, polypeptides and related methods |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| CN101160323A (zh) * | 2005-04-15 | 2008-04-09 | 拉帕波特家族医学科学研究所 | 用于治疗mcp-1/ccr2相关疾病的分子及其使用方法 |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| ES2560871T3 (es) | 2007-07-10 | 2016-02-23 | Apogenix Gmbh | Proteínas de fusión de colectina de la superfamilia de TNF |
| CA2726087A1 (en) | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| WO2010033315A1 (en) | 2008-09-22 | 2010-03-25 | Amgen Inc. | Method of treatment |
| JP2012504969A (ja) * | 2008-10-10 | 2012-03-01 | アナフォア インコーポレイテッド | Trail−r1及びtrail−r2に結合するポリペプチド |
| US8664366B2 (en) | 2009-01-09 | 2014-03-04 | Apogenix Gmbh | Fusion proteins forming trimers |
| JP2012515556A (ja) * | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法 |
| BR112012017164A2 (pt) | 2009-12-22 | 2019-09-24 | Novartis Ag | proteína de fusão de região constante de anticorpo-cd47 tetravalente |
| WO2011130324A1 (en) * | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
| EP2793947B1 (en) * | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
| EP3409686B1 (en) * | 2012-07-18 | 2022-04-13 | Apogenix AG | Composition comprising a mixture of cd95-fc isoforms |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/en not_active Withdrawn
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 PH PH1/2020/500377A patent/PH12020500377A1/en unknown
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh not_active IP Right Cessation
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/en active Active
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 SM SM20180286T patent/SMT201800286T1/it unknown
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en not_active Ceased
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 CA CA2946402A patent/CA2946402C/en active Active
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/en not_active Ceased
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh not_active Expired - Fee Related
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh not_active IP Right Cessation
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt not_active IP Right Cessation
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Ceased
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 CA CA3184067A patent/CA3184067A1/en active Pending
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko not_active Expired - Fee Related
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja not_active Expired - Fee Related
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 PH PH12016502079A patent/PH12016502079B1/en unknown
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en not_active Ceased
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja not_active Expired - Fee Related
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en not_active Abandoned
-
2024
- 2024-09-23 US US18/892,964 patent/US20250145688A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010010051A1 (en) * | 2008-07-21 | 2010-01-28 | Apogenix Gmbh | Tnfsf single chain molecules |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI747178B (zh) | 單鏈trail-受體激動劑蛋白質 | |
| ES2754432T3 (es) | Proteínas agonistas de receptor CD40 de cadena sencilla | |
| US10844108B2 (en) | Single-chain CD27-receptor agonist proteins | |
| US20210246190A1 (en) | Single-chain cd137-receptor agonist proteins | |
| US10683332B2 (en) | Single-chain light receptor agonist proteins | |
| US11149075B2 (en) | Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins | |
| US20180230196A1 (en) | Single-chain ox40-receptor agonist proteins | |
| HK1260151A1 (en) | Single-chain trail-receptor agonist proteins | |
| NZ725476B2 (en) | Single-chain trail-receptor agonist proteins | |
| HK1235072A1 (en) | Single-chain trail-receptor agonist proteins | |
| HK1235072B (en) | Single-chain trail-receptor agonist proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |